Trump administration cuts across federal health agencies have sent shivers through a biotech industry already struggling ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

The sector is defensive, and biopharmaceuticals have, for the most part, limited tariff and transfer price exposure, he ...

they have a significant influence over the performance of the biotech sector as a whole. While investors may not be able to capitalize on the catalysts that "made or broke" these companies in Q1 ...

According to analysts at Jefferies, legislation such as the newly proposed bills that aim to streamline regulatory processes ...

The drug and biotech sector has recovered over the past couple of months, following a slow start to the year, primarily due to the better-than-expected fourth-quarter performance of large ...

Omega Funds founder and managing director Otello Stampacchia isn’t afraid to tell it like he sees it.

From lab-grown actives to eco-friendly formulations, we reveal how biotech is reshaping the future of skin care, plus a round ...

The current macro environment appears grim, given the uncertainty around the global trade war, along with ongoing ...

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...